+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Medium Molecular Weight Polyisobutylene - Global Strategic Business Report

  • PDF Icon

    Report

  • 398 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6089368
The global market for Medium Molecular Weight Polyisobutylene was valued at US$4.3 Billion in 2025 and is projected to reach US$5.3 Billion by 2032, growing at a CAGR of 3.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Medium Molecular Weight Polyisobutylene (MMW PIB) Market - Key Trends & Drivers Summarized

Why Is Medium Molecular Weight Polyisobutylene Crucial Across Industrial Applications?

Medium molecular weight polyisobutylene (MMW PIB) is a versatile synthetic polymer that occupies a unique position between low molecular weight (liquid) and high molecular weight (rubbery solid) PIB grades. It exhibits excellent gas barrier properties, oxidation resistance, adhesion, tack, and flexibility, making it a critical component in products ranging from adhesives and sealants to lubricants, personal care formulations, and fuel additives.

MMW PIB is widely used in pressure-sensitive adhesives (PSAs), tire inner liners, and chewing gum bases due to its balance of viscosity and elastic modulus. In industrial applications, it serves as a plasticizer or viscosity modifier for elastomers and paraffinic oils. Its chemical inertness and UV resistance also make it ideal for sealants in construction, electrical insulation, and cable joint compounds. As demand rises for multifunctional, high-performance materials across sectors, MMW PIB's role is expanding beyond traditional markets.

How Are Manufacturing Advancements and Customization Driving PIB Innovation?

Technological progress in PIB polymerization and customization is enabling manufacturers to tailor viscosity, molecular weight distribution, and functional end groups to meet specific performance requirements. Controlled cationic polymerization and incorporation of reactive moieties are allowing PIB to be used as a precursor in specialty chemicals and elastomeric blends. The development of halogen-free and non-toxic PIB variants is increasing its appeal in applications demanding environmental and regulatory compliance.

Manufacturers are also improving dispersion characteristics and compatibility with other base polymers and oils, enabling more effective integration in multi-phase systems. This is especially valuable in high-performance adhesive formulations and lubricant blends where controlled tack, thermal resistance, and low volatility are critical. Moreover, MMW PIB is being used as an intermediate in polyisobutylene succinimide production - key for detergent additives in engine oils - broadening its industrial significance.

Which Industries and Products Are Driving Demand for MMW PIB Globally?

The automotive industry is one of the largest consumers of MMW PIB, particularly in tire manufacturing (for inner liners and sidewalls) and under-hood adhesives that require heat and gas resistance. The lubricant and fuel additive sector also uses MMW PIB for thickening agents, anti-mist formulations, and as a base for performance-enhancing chemicals. In the construction industry, MMW PIB is used in sealants for roofing membranes, double-glazing units, and vibration-damping systems.

Consumer goods and personal care applications are growing segments, where MMW PIB is valued for its smooth texture, film-forming ability, and water resistance - used in cosmetics, ointments, and barrier creams. The packaging industry utilizes PIB for cling films and wrap adhesives. In specialty chemical manufacturing, MMW PIB acts as a building block for advanced polymers and co-polymer formulations, enhancing mechanical properties and weather resistance.

The Growth in the Medium Molecular Weight PIB Market Is Driven by Several Factors

The growth in the medium molecular weight PIB market is driven by rising demand for performance adhesives, expanding automotive production, and the increased use of high-efficiency lubricant and fuel additives. A key driver is the material's unique balance of elasticity, impermeability, and thermal stability, which is ideal for demanding applications such as tire linings and industrial sealants. Environmental regulations are also prompting adoption of halogen-free, non-toxic alternatives where MMW PIB fits well.

The growth of the packaging and personal care industries is creating new use cases for PIB in formulations requiring skin-safe and moisture-resistant properties. Additionally, the continued development of high-performance elastomers and synthetic rubbers is reinforcing PIB's position as a critical blending agent. As end-user industries seek materials that offer durability, chemical inertness, and design flexibility, MMW PIB is expected to see sustained global demand across both mature and emerging applications.

Report Scope

The report analyzes the Medium Molecular Weight Polyisobutylene market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Type (Food-Grade Polyisobutylene, Industrial-Grade Polyisobutylene); Application (Adhesives, Sealants, Lubricants, Roofing, Packaging, Grease, Paraffin, Chewing Gums, Other Applications); End-Use (Automotive, Construction, Transportation, Chemical, Other End-Uses)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Food-Grade Polyisobutylene segment, which is expected to reach US$3.4 Billion by 2032 with a CAGR of a 2.4%. The Industrial-Grade Polyisobutylene segment is also set to grow at 4.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.2 Billion in 2025, and China, forecasted to grow at an impressive 5.1% CAGR to reach $1.0 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Medium Molecular Weight Polyisobutylene Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Medium Molecular Weight Polyisobutylene Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Medium Molecular Weight Polyisobutylene Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as BASF SE, Braskem S.A., Chevron Oronite Company LLC, Daelim Industrial Co., Ltd., Dow Chemical Company and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Medium Molecular Weight Polyisobutylene market report include:

  • BASF SE
  • Braskem S.A.
  • Chevron Oronite Company LLC
  • Daelim Industrial Co., Ltd.
  • Dow Chemical Company
  • Evonik Industries AG
  • ExxonMobil Chemical Company
  • INEOS Group Holdings S.A.
  • Infineum International Limited
  • JXTG Nippon Oil & Energy Corporation
  • KEMAT Polybutenes
  • Kothari Petrochemicals Limited
  • LANXESS AG
  • Lubrizol Corporation
  • Nizhnekamskneftekhim PJSC
  • Reliance Industries Limited
  • SIBUR Holding PJSC
  • TPC Group
  • Zhejiang Cenway Materials Co., Ltd.
  • Zhejiang Shunda New Material Co., Ltd

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Medullary Thyroid Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Awareness and Early Diagnosis Efforts Throw the Spotlight on Medullary Thyroid Cancer Detection Pathways
  • Advances in Genetic Screening Propel Growth in RET Mutation Testing and Targeted Therapy Eligibility
  • Increased Incidence of Sporadic and Hereditary MTC Expands the Addressable Market Opportunity for Targeted Therapeutics
  • Approvals of RET Inhibitors Strengthen the Business Case for Precision Medicine in MTC Management
  • Expansion of Next-Generation Sequencing (NGS) in Oncology Accelerates Demand for Molecular Diagnostic Solutions
  • Unmet Needs in Late-Stage and Metastatic MTC Drive Clinical Interest in Novel Combination Therapies
  • Growing Role of Multidisciplinary Care Models Sustains Demand for Coordinated Treatment Planning Tools
  • Tele-oncology and Remote Monitoring Trends Enhance Access to Specialist Care for MTC Patients in Underserved Regions
  • Pharmaceutical Innovation in Kinase Inhibitors Generates New Hope for Progressive or Refractory MTC Cases
  • Increased Use of Biomarkers like Calcitonin and CEA Drives Growth in Longitudinal Monitoring Solutions
  • Global Expansion of Cancer Genomics Programs Opens New Pathways for MTC Identification and Stratified Treatment
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Medullary Thyroid Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Radiation Therapy Center End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 26: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: USA Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: USA 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 32: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Canada Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Canada 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
JAPAN
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 38: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: Japan Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: Japan 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
CHINA
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 44: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 45: China Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: China 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
EUROPE
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 53: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: Europe 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
FRANCE
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 59: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: France Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: France 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
GERMANY
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 65: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Germany Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Germany 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 71: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: Italy Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: Italy 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 77: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: UK Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: UK 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Spain Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Spain 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 83: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Spain Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Spain 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Russia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Russia 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 89: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Russia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Russia 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 96: Rest of Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 97: Rest of Europe 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
ASIA-PACIFIC
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 100: Asia-Pacific 13-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 103: Asia-Pacific 13-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2020, 2026 & 2032
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 106: Asia-Pacific 13-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2020, 2026 & 2032
AUSTRALIA
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • BASF SE
  • Braskem S.A.
  • Chevron Oronite Company LLC
  • Daelim Industrial Co., Ltd.
  • Dow Chemical Company
  • Evonik Industries AG
  • ExxonMobil Chemical Company
  • INEOS Group Holdings S.A.
  • Infineum International Limited
  • JXTG Nippon Oil & Energy Corporation
  • KEMAT Polybutenes
  • Kothari Petrochemicals Limited
  • LANXESS AG
  • Lubrizol Corporation
  • Nizhnekamskneftekhim PJSC
  • Reliance Industries Limited
  • SIBUR Holding PJSC
  • TPC Group
  • Zhejiang Cenway Materials Co., Ltd.
  • Zhejiang Shunda New Material Co., Ltd

Table Information